Who is sponsoring NCT04525248?

NCT04525248 is sponsored by Shanghai Minimally Invasive Surgery Center.

What drugs are being tested in NCT04525248?

Interventions in NCT04525248: Laparoscopic total colectomy + low resection of rectum, Laparoscopic total colectomy + High resection of rectum.

What condition does NCT04525248 study?

NCT04525248 studies Slow Transit, Constipation.

Is NCT04525248 still recruiting?

NCT04525248 is currently status unknown. Last updated 25 August 2020.

Last reviewed 2020-08-25 · How we verify

NCT04525248

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Resection Location of Rectum in Laparoscopic Surgery for Slow Transit Constipation

Status unknown NA Last updated 25 August 2020

What this trial tests

NA trial testing Laparoscopic total colectomy + low resection of rectum in Slow Transit in 78 participants. Status unknown.

Timeline

1 September 2020

Primary endpoint
1 August 2023

1 August 2024

Quick facts

Lead sponsor	Shanghai Minimally Invasive Surgery Center
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	78
Start date	1 September 2020
Primary completion	1 August 2023
Estimated completion	1 August 2024

Drugs / interventions tested

Laparoscopic total colectomy + low resection of rectum
Laparoscopic total colectomy + High resection of rectum

Conditions studied

Slow Transit — all drugs for Slow Transit →
Constipation — all drugs for Constipation →

Sponsor

Shanghai Minimally Invasive Surgery Center — full company profile →

Who can join

Adults 15 to 75, any sex, with Slow Transit or Constipation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study the recurrence rate of constipation after laparoscopic total colectomy with high resection or low resection of rectum

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai Minimally Invasive Surgery Center trials

Trials by the same sponsor.

NCT07076979 — Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer：MetB · recruiting
NCT07068529 — Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer：M · recruiting
NCT06746298 — A Prospective Study of Expression Profiling-based Assessment of the Efficacy of Neoadjuvant Therapy for Rectal Cancer · not yet recruiting
NCT04620473 — Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer · Phase 2 · withdrawn
NCT05495048 — Transvaginal NOSES Versus Conventional Laparoscopic Surgery for Right Hemicolectomy · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04525248 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Minimally Invasive Surgery Center
Last refreshed: 25 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04525248.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing